A plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma
A new plain language summary discussing the results of a clinical study that looked at the use of two immunotherapy drugs, pembrolizumab and ipilimumab, for the treatment of advanced melanoma.